Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo
Open Access
- 24 August 2012
- journal article
- Published by Springer Nature in Experimental & Translational Stroke Medicine
- Vol. 4 (1) , 16
Abstract
Background: Intracerebral administration of the angiotensin II type 2 receptor (AT2R) agonist, CGP42112, is neuroprotective in a rat model of ischemic stroke. To explore further its possible cellular target(s) and therapeutic utility, we firstly examined whether CGP42112 may exert direct protective effects on primary neurons following glucose deprivation in vitro. Secondly, we tested whether CGP42112 is effective when administered systemically in a mouse model of cerebral ischemia. Methods: Primary cortical neurons were cultured from E17 C57Bl6 mouse embryos for 9 d, exposed to glucose deprivation for 24 h alone or with drug treatments, and percent cell survival assessed using trypan blue exclusion. Ischemic stroke was induced in adult male C57Bl6 mice by middle cerebral artery occlusion for 30 min, followed by reperfusion for 23.5 h. Neurological assessment was performed and then mice were euthanized and infarct and edema volume were analysed. Results: During glucose deprivation, CGP42112 (1x10-8 M and 1x10-7 M) reduced cell death by ~30%, an effect that was prevented by the AT2R antagonist, PD123319 (1x10-6 M). Neuroprotection by CGP42112 was lost at a higher concentration (1x10-6 M) but was unmasked by co-application with the AT1R antagonist, candesartan (1x10-7 M). By contrast, Compound 21 (1x10-8 M to 1x10-6 M), a second AT2R agonist, had no effect on neuronal survival. Mice treated with CGP42112 (1 mg/kg i.p.) after cerebral ischemia had improved functional outcomes over vehicle-treated mice as well as reduced total and cortical infarct volumes. Conclusions: These results indicate that CGP42112 can directly protect neurons from ischemia-like injury in vitro via activation of AT2Rs, an effect opposed by AT1R activation at high concentrations. Furthermore, systemic administration of CGP42112 can reduce functional deficits and infarct volume following cerebral ischemia in vivo.Keywords
This publication has 31 references indexed in Scilit:
- Mechanisms Contributing to Cerebral Infarct Size after Stroke: Gender, Reperfusion, T Lymphocytes, and Nox2-Derived SuperoxideJournal of Cerebral Blood Flow & Metabolism, 2010
- Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damageJournal Of Hypertension, 2009
- Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potentialJournal of the Renin-Angiotensin-Aldosterone System, 2009
- Angiotensin AT 2 Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of StrokeStroke, 2009
- The development of stroke therapeutics: Promising mechanisms and translational challengesNeuropharmacology, 2009
- Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell deathProceedings of the National Academy of Sciences, 2007
- Angiotensin II Type-2 Receptor Stimulation Prevents Neural Damage by Transcriptional Activation of Methyl Methanesulfonate Sensitive 2Hypertension, 2006
- The ACCESS StudyStroke, 2003
- Adventures in the Pathophysiology of Brain Ischemia: Penumbra, Gene Expression, NeuroprotectionStroke, 2003
- Blockade of Central Angiotensin AT1Receptors Improves Neurological Outcome and Reduces Expression of AP-1 Transcription Factors After Focal Brain Ischemia in RatsStroke, 1999